期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 6, 期 4, 页码 375-380出版社
AMER CHEMICAL SOC
DOI: 10.1021/ml500154q
关键词
ML278; SR-BI inhibitor; HDL receptor; reverse cholesterol transport; indoline; thiazole; HTS; MLP; HCV
资金
- NIH-MLPCN program [1 U54 HG005032-1]
- NIH [HL052212, HL066105]
A potent class of indolinyl-thiazole based inhibitors of cellular lipid uptake mediated by scavenger receptor, class B, type I (SR-BI) was identified via a high-hroughput screen of the National Institutes of Health Molecular Libraries Small Molecule Repository (NIH MLSMR) in an assay measuring the uptake of the fluorescent lipid DiI from HDL particles. This class of compounds is represented by ML278 (17-11), a potent (average IC50 = 6 nM) and reversible inhibitor of lipid uptake via SR-BI. ML278 is a plasma-stable, noncytotoxic probe that exhibits moderate metabolic stability, thus displaying improved properties for in vitro and in vivo studies. Strikingly, ML278 and previously described inhibitors of lipid transport share the property of increasing the binding of HDL to SR-BI, rather than blocking it, suggesting there may be similarities in their mechanisms of action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据